Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.


Clinical Trial Description

Preeclampsia is a serious disease of pregnancy that manifests with increased blood pressure and can affect all the organs in a woman's body. It usually develops after 20 weeks of pregnancy. There is an abnormal amount of protein in the urine and with worsening disease known as "severe features," patients can have pain in the upper abdomen, changes in vision, fluid in the lungs, an intense headache, low number of platelets in the blood, and abnormal liver or kidney function. Very high blood pressure is also considered a severe feature. The exact cause of preeclampsia is unknown but women with the condition are at increased risk for complications during pregnancy, including seizures - eclampsia. Babies are at risk of being born premature because the only cure for preeclampsia is delivery. Women who have had preeclampsia are also at increased risk of cardiovascular and kidney disease later in life, including heart attack, stroke and high blood pressure. Studies show that women at high risk for preeclampsia, i.e., have had preeclampsia in a prior pregnancy, are carrying more than one fetus, have a history of high blood pressure, kidney disease or both, have certain medical problems such as diabetes, thrombophilia or lupus, have a modestly decreased risk of disease with daily intake of low-dose aspirin starting after 12 weeks of pregnancy. Due to the limited data available on the topic of LDA in preeclamptic patients in the postpartum period, particularly as applicable to the American population, the investigator intends to start with a small pilot study involving the collection of information on 10 women not exposed to study intervention. This will allow for confirmation of the sample size based on the baseline FMD measurements 2 days after delivery. Investigator will also explore a small sub-study to gather information regarding baseline FMD and biomarker values for healthy control postpartum patients, unaffected by preeclampsia and not on LDA during pregnancy or postpartum. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03667326
Study type Interventional
Source Columbia University
Contact Aleha Aziz, MD, MPH
Phone 646-678-0289
Email aa4065@cumc.columbia.edu
Status Recruiting
Phase Phase 2
Start date July 22, 2019
Completion date December 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05534932 - Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women N/A
Recruiting NCT04632589 - Losartan for Improved Vascular Endothelial Function After Preeclampsia Early Phase 1
Not yet recruiting NCT06373367 - Preeclampsia Educational Program Study (PrEPS) N/A
Recruiting NCT05937841 - Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia Early Phase 1
Recruiting NCT03978767 - Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial Phase 2
Recruiting NCT05924971 - Aspirin for Postpartum Patients With Preeclampsia Phase 2
Not yet recruiting NCT06353256 - A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes N/A
Recruiting NCT04479072 - Aspirin and Preeclampsia Phase 4
Completed NCT03451266 - Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia Phase 1